Business Wire

Aircall Exceeds $100 Million in Annual Recurring Revenue, and Reaches Centaur Status

Share

Aircall, the connected business phone, today announced it has passed $100 Million in Annual Recurring Revenue (ARR), reaching the exclusive centaur status that only about 150 private companies in the cloud industry, worldwide, have achieved. This milestone comes 6 years after its first million dollar ARR reached in March 2016. Since its last funding round in June 2021, which catapulted the company to a billion dollar valuation, Aircall has recorded 70% YoY growth in revenue and a 107% YoY increase of large customers.

Olivier Pailhès, Aircall co-founder and CEO,said:We’ve seen businesses worldwide evaluating the current economic environment and increasingly looking for simple phone systems and call center softwares that are easy to implement and increase efficiency and productivity, but also improve the quality of their customer experience. We’re delighted to reach this milestone as a company, as it represents the continued value we bring to customers around the world and helps further our mission of empowering every professional to have richer conversations.”

Aircall maintains its growth trajectory by focusing on fundamentals, that include continuing to enrich its marketplace, to empower every professional to have richer conversations. This ecosystem currently integrates with more than 100 leading business tools, including Salesforce, HubSpot, Microsoft Teams, Intercom and more. The company keeps scaling up its investment in R&D, focusing on addressing bigger customers in the mid-market segment. Aircall’s growth relies strongly on internationalization, and following the success of its North America headquarters, the company continues to open new offices in cities around the globe, with plans to expand in Singapore and Madrid later this year.

Jonathan Anguelov, Aircall co-founder and General Manager, added:“We're very proud of reaching this milestone just 6 years after our first million dollars of revenue. This is a strong indication of the worldwide demand for technology solutions. Reaching $100m ARR is an important metric and it offers a valuable perspective on how Aircall is performing in a volatile market. It also brings us a step closer to public scale. After opening offices in Australia, UK and Germany, we’re excited to continue our expansion worldwide and keep building a team that is pushing what cloud-based phone solutions can offer.”

About Aircall

Aircall is the phone system of choice for modern businesses. An entirely cloud-based voice platform that integrates with popular productivity and help desk tools such as Salesforce, HubSpot, Slack, and many others. Aircall was built to make phone support easy to manage, accessible, transparent, and collaborative. Aircall believes that voice is the most powerful way to communicate with customers, prospects, candidates, and colleagues. It is designed to enable delightful moments of human connection. Aircall was founded in 2014 and has raised over $226 million in funding. With offices in New York, Paris, Sydney, Berlin, London, and soon in Madrid and Singapore, the company currently has over 700+ employees, and 12 000+ customers, such as untuckit, Brooklinen, Scotch & Soda, Birchbox, Milk Bar, Pier 1, Venus et Fleur.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Aircall UK PR Contact
Archetype for Aircall
aircall@archetype.co

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF Unveils Nourish Innovation Lab in Union Beach, New Jersey19.8.2022 12:55:00 CEST | Press release

IFF (NYSE:IFF) today announced the opening of its new Nourish Innovation Lab at the company’s Union Beach, New Jersey research and development center. In the state-of-the-art lab, scientists—including flavorists and food designers—will leverage tools, technologies and ingredient expertise to offer customers full product design, driving growth in the global food and beverage markets by fast forwarding innovation. “This new facility is a testament to how we pioneer innovation and drive speed to market and accessibility to our customers,” said Nicolas Mirzayantz, president of Nourish, IFF. “We will nurture an innovation project from concept to kitchen table, under one roof. Using our scientific knowhow, application excellence and full portfolio of ingredients, we’ll improve the taste and nutrition profiles of next-generation food and beverages. With our new culinary kitchen, we’re enabling technology focused on the consumer-eating experience, taking food development out of the traditional

PUMA Ambassador and European Champion Gianmarco Tamberi Talks “Only See Great”19.8.2022 11:52:00 CEST | Press release

Six years after his first gold medal, Tamberi takes back the European title and speaks about his motivation to keep performing at the highest level in a video interview with sports company PUMA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220819005125/en/ Six years after his first gold medal, Tamberi takes back the European title and speaks about his motivation to keep performing at the highest level in a video interview with sports company PUMA. (Photo: Business Wire) With the ‘Only See Great’ campaign, PUMA explores the career path of its brand ambassadors, as they talk about their own pursuit of greatness, listening to their hearts, and finding a vision that no one else can see. In the interview, Gianmarco talks about his very first successes and extraordinary performance at the Olympic Games in Tokyo. “That feeling that I had that day, that happiness I couldn’t even imagine that could exist. It’s something that was co

Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)19.8.2022 10:30:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the European Commission (EC) approved CRYSVITA® (burosumab) for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed in the EU for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with fewer than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with progressive and debilitating musculoskeletal deficits,6,7 ultimately having a detr

Kapruvia ® approved in Switzerland with additional regulatory decisions expected in H2 202219.8.2022 07:00:00 CEST | Press release

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005552/en/ “The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a

European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer19.8.2022 04:47:00 CEST | Press release

Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin®, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer. “The European Commission’s approval of Vegzelma™ will increase access to treatment for patients living with certain types of cancer at an affordable price,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “With proven similarities in efficacy and safety compared to the reference product Avastin®, Vegzelma™ will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.” The EC approval of Vegzelma™ follows the recommendation for marketing authorisation issued by the Committee for Medi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom